Management of venous thromboembolism in patients with cancer: role of dalteparin
Lori-Ann LinkinsDepartment of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, CanadaAbstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients du...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-04-01
|
| Series: | Vascular Health and Risk Management |
| Online Access: | https://www.dovepress.com/management-of-venous-thromboembolism-in-patients-with-cancer-role-of-d-peer-reviewed-article-VHRM |
| _version_ | 1818542745319374848 |
|---|---|
| author | Lori-Ann Linkins |
| author_facet | Lori-Ann Linkins |
| author_sort | Lori-Ann Linkins |
| collection | DOAJ |
| description | Lori-Ann LinkinsDepartment of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, CanadaAbstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.Keywords: dalteparin, cancer, venous thromboembolism |
| first_indexed | 2024-12-11T22:26:10Z |
| format | Article |
| id | doaj.art-8557782826424142b2da55e74cbedfa6 |
| institution | Directory Open Access Journal |
| issn | 1178-2048 |
| language | English |
| last_indexed | 2024-12-11T22:26:10Z |
| publishDate | 2008-04-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Vascular Health and Risk Management |
| spelling | doaj.art-8557782826424142b2da55e74cbedfa62022-12-22T00:48:17ZengDove Medical PressVascular Health and Risk Management1178-20482008-04-01Volume 42792871608Management of venous thromboembolism in patients with cancer: role of dalteparinLori-Ann LinkinsLori-Ann LinkinsDepartment of Hematology and Thrombosis, McMaster University, Hamilton, Ontario, CanadaAbstract: Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.Keywords: dalteparin, cancer, venous thromboembolismhttps://www.dovepress.com/management-of-venous-thromboembolism-in-patients-with-cancer-role-of-d-peer-reviewed-article-VHRM |
| spellingShingle | Lori-Ann Linkins Management of venous thromboembolism in patients with cancer: role of dalteparin Vascular Health and Risk Management |
| title | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| title_full | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| title_fullStr | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| title_full_unstemmed | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| title_short | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| title_sort | management of venous thromboembolism in patients with cancer role of dalteparin |
| url | https://www.dovepress.com/management-of-venous-thromboembolism-in-patients-with-cancer-role-of-d-peer-reviewed-article-VHRM |
| work_keys_str_mv | AT loriannlinkins managementofvenousthromboembolisminpatientswithcancerroleofdalteparin |